| abstract |
The present invention relates to heterogeneous niche activity in mesenchymal stromal cell-based cell therapy. It was discovered in the present invention that a difference in the niche activities of MSCs can be created during ex-vivo expansion of MSCs to cause a variation in the outcomes of hematopoietic recoveries. Particularly, the difference is caused by the functional state of MSCs derived by distinct upstream signaling pathways, rather than by clonal heterogeneity, and the functional state can be inferred through the CFU-F of MSC. Therefore, the present invention is expected to contribute to solving a variation in therapeutic effects which is pointed out as a problem of conventional mesenchymal stromal cell-based cell therapy. |